Figure 1. Snai2 is specifically expressed in bone marrow MSPCs.

(A) Expression of EMT factors in Nes-GFP^Hi and Nes-GFP^Lo cells from previous RNA-seq analysis (Kunisaki et al., 2013). (B) Immunofluorescence images of whole-mount sterna from Snai2-YFP; Ng2-Cre; R26-tdTomato mice. A647-conjugated anti-CD31/CD144 antibodies were injected intravenously to label functional blood vessels. Scale bar=50μm. (C) FACS plot of CD45⁻ Ter119⁻ CD31⁻ BM cells and quantifications showing nearly complete overlap between Snai2-YFP and Ng2-Cre; R26-tdTomato expression (n=3). (D) FACS plot showing restricted Snai2-YFP expression in the CD45⁻ Ter119⁻ fraction of the BM nucleated cells (BMNCs). (E) FACS plot showing Snai2-YFP labels mostly CD45⁻ Ter119⁻ CD31⁻ CD51⁺PDGFRα⁺ MSPCs. (F) FACS plot showing that most CD45⁻ Ter119⁻ CD31⁻ CD51⁺PDGFRα⁺ MSPCs are Snai2-YFP⁺. (G) qRT-PCR analysis of Snai2 mRNA expression in sorted MSPC and hematopoietic stem and progenitor populations (Nes-GFP^hi and GFP^lo: CD45⁻ Ter119⁻ CD31⁻Nes-GFP^high and GFP^low respectively. LT-HSC: long term HSCs, ST-HSC: short term HSC, MPP: multipotent progenitors, MEP: megakaryocyte-erythrocyte progenitors, CMP: common myeloid progenitors, GMP: granulocyte-macrophage progenitors). (H) Niche factor mRNA levels in sorted CD45⁻ Ter119⁻ CD31⁻ stromal populations from Snai2-YFP BM. (I) Colony forming unit-fibroblast (CFU-F) activity of sorted CD45⁻ Ter119⁻ CD31⁻ stromal populations from Snai2-YFP BM.